| First trimester maternal serum pregnancy-specific beta-1-glycoprotein (SP1) as a marker of adverse pregnancy outcome. | |
| | |
MedLine Citation:
|
PMID: 19911417 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
OBJECTIVE: To establish the first trimester levels of pregnancy-specific beta-1-glycoprotein (SP1) in pregnancies with adverse outcome. Furthermore, to determine the screening performance for adverse outcome using SP1 alone and in combination with other first trimester markers including proMBP and PAPP-A. METHODS: A case-control study was conducted in a primary hospital setting. The SP1 concentration was measured in first trimester maternal serum in pregnancies with small-for-gestational age fetuses (SGA) (n = 150), spontaneous preterm delivery (n = 88), preeclampsia (n = 40) and in controls (n = 500). Concentrations were converted to multiples of the median (MoM) in controls and groups were compared using Mann-Whitney U-test. Logistic regression analysis was used to determine significant factors for predicting adverse pregnancy outcome. Screening performance was assessed using receiver operating characteristic (ROC) curves. RESULTS: The SP1 MoM median was significantly reduced in cases with SGA (0.76 MoM, p < 0.0005) and spontaneous preterm delivery (0.77 MoM, p < 0.0005) whereas no alteration was found in cases with preeclampsia (0.94 MoM, p = 0.723). A significant correlation (r = 0.217) between log(10)(SP1 MoM) and the birth weight percentile was found in the SGA group. Screening performance was only slightly improved when SP1 was combined with PAPP-A or proMBP. CONCLUSION: SP1 is a first trimester maternal serum marker of SGA and preterm delivery. |
| | |
Authors:
|
Kasper Pihl; Torben Larsen; Inga Laursen; Lone Krebs; Michael Christiansen |
Related Documents
:
|
19644947 - Hypertensive disorders in pregnancy: screening by uterine artery doppler at 11-13 weeks. 12636947 - Incorporation of inhibin-a in second-trimester screening for down syndrome. 17353687 - First and early second trimester fetal heart screening. 4024877 - Screening in pregnancy with unconjugated estriol compared with total estriol. 979197 - Damage risk: an evaluation of the effects of exposure to 85 versus 90 dba of noise. 17297257 - Prediction of prolonged pregnancy in nulliparous women by transvaginal ultrasonographic... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Prenatal diagnosis Volume: 29 ISSN: 1097-0223 ISO Abbreviation: Prenat. Diagn. Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2009-12-07 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8106540 Medline TA: Prenat Diagn Country: England |
Other Details:
|
Languages: eng Pagination: 1256-61 Citation Subset: IM |
Copyright Information:
|
Copyright (c) 2009 John Wiley & Sons, Ltd. |
Affiliation:
|
Department of Clinical Biochemistry and Immunology, Statens Serum Institut, Copenhagen, Denmark. Kasper_Pihl@dadlnet.dk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The complete three-vessel view in prenatal detection of congenital heart defects.
Next Document: First-trimester fetal nasal bone audit: evaluation of a novel method of image assessment.